Here's one article I found online that mentions it:
http://www.nytimes.com/2011/08/07/opinion/sunday/ezekiel-emanuel-cancer-patients.html
Thanks for sharing and I can’t disagree that Oncologists are using the more expensive drugs as a result of shortages.
I work in the industry. I don’t think pharma co’s are purposefully discontinuing older generics in order to direct sales to their higher margins ones, and I’m glad to see that the article did not infer that. The reason the higher margin drugs remain widely available is that they have adequate capacity (in some cases dual sourced) and modern / compliant (to today’s standard) production methods.